Learn how early regulatory engagement, validated digital systems, and robust protocol design enable biotechs to run parallel ...
At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients ...
At ESMO 2025, Eli Lilly’s Verzenio and Novartis’ Kisqali both demonstrated durable efficacy in hormone receptor-positive, ...
In this week’s Applied Clinical Trials Brief, we highlight key findings from the 2025 State of the Industry Survey, explore how AI is transforming trial efficiency and patient engagement, and examine ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
New results from the Phase III MATTERHORN trial show AstraZeneca’s Imfinzi combination reduced the risk of death by 22% versus chemotherapy alone, marking a major advance for patients with resectable ...
See how early patient inclusion, integrated regulatory planning, and seamless CRO partnerships can help biotechs accelerate ...
View the Applied Clinical Trials October 2025 issue in an interactive format.
Patient-reported outcomes (PROs) are widely used in oncology clinical trials to capture patients’ own perspectives on ...
Praxis Precision Medicines has shared positive data from its Phase III Essential3 clinical trial program (NCT06087276) assessing ulixacaltamide in essential tremor (ET). Across two studies, the small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback